Fatigue News and Research

RSS

Vaccine and drug combination cuts melanoma recurrence by half

The combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence by 49 percent, a new study shows.

1 Jun 2026

Apple Watch app detects seizures with 98% accuracy

The EpiWatch app shows high sensitivity in detecting tonic-clonic seizures in children and adults, potentially reducing SUDEP risk with timely alerts.

1 Jun 2026

Higher-dose ocrelizumab depletes more B cells but does not slow MS progression

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.

31 May 2026

Mount Sinai study links long COVID symptoms to autoimmunity

A Mount Sinai-led research team has demonstrated that autoimmunity, where the body's immune system attacks its own tissues, is responsible for the often-debilitating and confounding symptoms of long COVID in a subset of people.

28 May 2026

Vitamin deficiencies may contribute to chronic fatigue and low motivation

With less time and more work, chronic fatigue has become a moniker of modern society. However, this not only reduces the quality of life but also constitutes as a social issue that affects work efficiency and leads to accidents.

28 May 2026

EEG reveals how coffee may secretly lower sleep quality

Evening coffee has sparked controversy for years. Some people fall asleep without difficulty, while others toss and turn for half the night.

27 May 2026

Climate change could expand chikungunya into temperate regions worldwide

Chikungunya ('to become contorted' in the Kimakonde language, named after the characteristic joint ache) is classified as one of the neglected tropical diseases by the World Health Organization.

27 May 2026

Guava juice boosts hemoglobin levels in women with anemia

Regular guava juice consumption may prove a readily accessible and affordable addition to helping lower the risk of anemia in women in low and middle income countries, suggests a synthesis of the available evidence, published in the open access journal BMJ Nutrition Prevention & Health.

26 May 2026

Special yoga intervention helps cancer survivors manage psychological side effects

University of Rochester Medicine is in the spotlight at a national meeting for a new discovery in integrative oncology: A special yoga intervention, the study shows, goes a step further than other side-effect therapies to improve four domains of physical and psychological side effects that most patients experience, including lifting mood and easing anxiety.

26 May 2026

Gay dating apps during travel bring connection and emotional fatigue

New research shows that gay dating apps during travel can bring excitement and connection - but also emotional exhaustion, catfishing, and vulnerability.

25 May 2026

Study identifies major causes of fatigue among disaster responders

Real time data collected during the 2024 Noto Peninsula earthquake response show that unclear tasks and command structures, and lack of meal- and rest breaks increased self-reported fatigue among disaster responders.

22 May 2026

Brain scans find no evidence of widespread inflammation in long COVID

A new brain imaging study has found no evidence of widespread brain inflammation in patients suffering from prolonged symptoms after COVID-19 infection. Instead, the most severe long COVID symptoms were associated with increased brain activity in regions involved in mood and emotion.

22 May 2026

Squid™ Full Range Pipette: Reduce pipette changes, bench clutter, and calibration burden

The Squid Full Range Pipette covers 1–1000 µL in one device, reducing pipette changes, bench clutter, calibration burden, and workflow fatigue.

From DeNovix Inc. 22 May 2026

How screen time, stress, and nicotine trap young adults in poor sleep

Among the younger part of the population, sleep problems, anxiety, and depression are widespread and growing issues.

22 May 2026

Could blocking inflammation help treat difficult-to-treat depression?

A small proof-of-concept RCT found that tocilizumab, an IL-6 receptor blocker, showed a non-significant but clinically suggestive pattern of improvement in difficult-to-treat depression linked to low-grade inflammation. The study found that baseline hs-CRP, rather than IL-6, may help identify patients most likely to respond, supporting larger trials of immune-targeted depression care.

22 May 2026

Study supports routine childhood screening for type 1 diabetes

For ten years, the Fr1da study, coordinated by Helmholtz Munich, has been investigating whether early stages of type 1 diabetes in children can be detected in routine pediatric care.

21 May 2026

Researchers discover how overpopulation reduces fertility

Scientists have reported it for decades: Overpopulation can impair reproduction.

21 May 2026

Phase two clinical trial demonstrates dramatic mobility gains in children with severe fibrous dysplasia

Fibrous dysplasia is a rare skeletal disorder in which normal bone is gradually replaced by weak fibro-osseous tissue, leading to fractures, pain, deformities, and severe mobility impairment. In many patients, diseased bone tissue produces excessive amounts of fibroblast growth factor-23 (FGF23), a hormone that causes phosphate loss through the kidneys.

21 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026

Anti-inflammatory drug tocilizumab shows promise for difficult-to-treat depression

Immunotherapy could be a promising new treatment option for patients with difficult-to-treat depression. This is a key finding from a University of Bristol-led pilot randomised controlled clinical trial, published in JAMA Psychiatry today [20 May].

20 May 2026